Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
Ozempic Lawsuits Claim Drug Is Linked to Vision Loss - Featured image
Health

Ozempic Lawsuits Claim Drug Is Linked to Vision Loss

Ozempic, along with other weight loss medications, has demonstrated potential in mitigating health risks. However, lawsuits are emerging, alleging a connection between these drugs and vision loss. Patients are filing claims against the manufacturers.

Shotlee·December 19, 2025·Updated Jan 27, 2026·2 min read
Share:

Ozempic Lawsuits Claim Drug Is Linked to Vision Loss

Weight loss drugs like Ozempic have been shown to decrease risks for various health problems, including heart and kidney disease, potentially generating billions in revenue for pharmaceutical companies over the coming decade.

However, in rare instances, GLP-1 agonists, the class of drugs to which Ozempic belongs, can lead to severe side effects. Most notably, blindness has been reported, prompting over 70 lawsuits against Novo Nordisk and Eli Lilly, the makers of Ozempic and Mounjaro, respectively, according to Reuters.

These lawsuits, filed in both state and federal courts, claim that the medications caused patients to develop non-arteritic anterior ischemic optic neuropathy. This condition involves a disruption of blood flow to the optic nerve, resulting in vision loss. Health tracking apps like Shotlee can help monitor for any sudden changes in vision, facilitating early detection and intervention.

A federal judicial panel recently approved the consolidation of these cases, assigning a Pennsylvania federal judge to oversee them. This decision paves the way for a significant legal battle with potentially far-reaching consequences for the future of these increasingly popular drugs.

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Become aBeta Tester

Furthermore, the manufacturers of GLP-1 drugs face additional challenges beyond the blindness lawsuits. A separate series of legal actions alleges that these drugs can induce gastroparesis, a condition where the gastrointestinal tract's ability to move food for digestion is impaired.

The first GLP-1 agonist drug received approval from the US Food and Drug Administration (FDA) in 2005 as a treatment for diabetes. Subsequently, in 2021, the FDA authorized Novo Nordisk, the manufacturer of Ozempic, to produce and market Wegovy. Wegovy functions similarly to Ozempic but is specifically targeted towards individuals seeking weight loss.

That important decision, coupled with widespread positive media coverage, sparked the current enthusiasm for these weight loss medications. Celebrities such as Oprah and Rebel Wilson have reportedly experienced significant weight loss in a relatively short period using these drugs.

However, in recent years, an increasing number of individuals have reported experiencing serious side effects from using these medications. This has tempered some of the excitement surrounding drugs that were once promoted as a miracle cure for a wide array of ailments, including aging.

Original source: Futurism

View original article →
#Ozempic#lawsuits#blindness#weight loss drugs#Novo Nordisk#Eli Lilly#vision loss#GLP-1 agonists
  1. Home
  2. Blog
  3. Ozempic Lawsuits Claim Drug Is Linked to Vision Loss

Related Articles

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds
GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report
Metabolic Health

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report

Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community